Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies.
OBJECTIVE
To report a severe adverse event related to enzyme replacement therapy with agalsidase in an hemizygous male patient treated for Fabry disease.


METHODS
Retrospective analysis of clinical, radiological and biochemical data in a patient who suffered adverse events related to both agalsidase alfa and agalsidase beta treatments.


RESULTS
A hemizygous male patient was first treated for Fabry disease with agalsidase alfa. After more than 1 year of therapy, infusion-related symptoms necessitated systemic steroids and antihistaminic therapy. Decline in kidney function prompted a switch for agalsidase beta. Anaphylactoid shock occurred after the second infusion. No serum IgE antibodies were disclosed. Skin-test reactivity to agalsidase beta was negative. Following a published rechallenge infusion protocol, agalsidase beta was reintroduced, leading to a second anaphylactoid shock episode. Enzyme replacement therapy was stopped and the patient was treated with symptomatic therapy only. This case was referred to the pharmacovigilance department.


CONCLUSIONS
The negativity of immunological tests (specific anti-agalsidase IgE antibodies and skin tests) does not rule out the risk of repeated anaphylactoid shock following agalsidase infusion.
Tesmoingt
Chloe
C
Department of Clinical Pharmacy, Bichat-Claude Bernard University Hospital (AP-HP), Paris, France.
Lidove
Olivier
O
Reberga
Axele
A
Thetis
Marguerite
M
Ackaert
Chloe
C
Nicaise
Pascale
P
Arnaud
Philippe
P
Papo
Thomas
T
D000328:Adult; D000707:Anaphylaxis / Q000139:chemically induced*; D000888:Antibodies, Anti-Idiotypic / Q000009:adverse effects*; D056947:Enzyme Replacement Therapy / Q000009:adverse effects*; D000795:Fabry Disease / Q000188:drug therapy*; D006801:Humans; D007527:Isoenzymes / Q000009:adverse effects; D008297:Male; D011994:Recombinant Proteins; D012307:Risk Factors; D016896:Treatment Outcome; D000519:alpha-Galactosidase / Q000009:adverse effects
D000888:Antibodies, Anti-Idiotypic; D007527:Isoenzymes; D011994:Recombinant Proteins; C048844:anti-IgG; C000627036:agalsidase alfa; D000519:alpha-Galactosidase; C459420:agalsidase beta